Anebulo Pharmaceuticals, Inc. Commences Tender Offer to Support "Go Private" Plan

Anebulo Pharmaceuticals, Inc. announced its intention to commence a cash tender offer on December 22, 2025, to purchase up to 300,000 shares of its common stock at $3.50 per share. This tender offer is part of the company's strategy to "go private" and replaces a previously planned reverse stock split. The decision to abandon the reverse stock split was due to concerns about increased costs associated with shareholders acquiring shares in multiple small accounts to manipulate fractional share payments. The tender offer aims to reduce the number of stockholders to below 300, a requirement for the "go private" transaction. The company reserves the right to reconsider a reverse stock split or alternative transactions in the future. The tender offer materials will be filed with the SEC and made available to stockholders. Anebulo Pharmaceuticals is a clinical-stage company developing treatments for cannabis-induced toxicity.